GE HealthCare Technologies Inc.

Good day and thank you for standing by. Welcome to the GE Healthcare Second Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that this conference is being recorded. I would now like to turn the conference over to your speaker today, Carolyn Borders. Please go ahead.

Thanks, operator. Good morning and welcome to GE Healthcare Second Quarter 2025 Earnings Call. I'm joined by our President and CEO, Peter Arduini, and Vice President and CFO, Jay Sakharo. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliation between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I'll hand the call over to Peter.

Thanks, Carolyn. Good morning and thank you all for joining today. I'm pleased to report that we delivered another solid quarter marked by continued business execution, healthy customer demand, and ongoing progress with our Precision Care Strategy. In the second quarter, we saw orders growth across all segments. Backlog remains at record levels and strong -to-bill reflects continued customer investment in capital equipment. For example, we're seeing this in imaging and advanced visualization solutions for outpatient cardiac and orthopedic settings. We're also observing healthy procedure volumes globally. Revenue growth in the period was driven by strength in the US and EMEA regions. Looking at commercial execution, I'd like to highlight significant wins and long-term enterprise deals that demonstrate our continued momentum. During the second quarter, in the US, we secured our largest order ever of Omni-Legend PET-CT systems. We also entered a strategic collaboration with Ascension, valued up to $90 million in the first year. We broadened our long-term relationship with one of the largest providers in Mexico and secured a $250 million five-year collaboration in Europe. These strategic collaborations leverage our D3 strategy, which is about bringing to market world-class solutions with smart devices and drugs, enabling disease-state solutions with digital and AI. Success in our global strategy is evidenced by the adoption of new product introductions, which generated over 50% of our sales. This demonstrates the success of our R&D investments. Our commercial teams go to market with a solutions mindset, clinical expertise, and deep product domain. All of this enables us to better serve patient needs and help our customers create sustainable long-term growth. In the quarter, we delivered strong EPS despite a mixed macroeconomic landscape. Overall, we're optimistic given customer investment, our operational execution, and increasing clarity in the global trade landscape. Now, I'll turn the call over to Jay to provide more details